Literature DB >> 6837886

Aggressive surgical management of popliteal artery aneurysms.

M K Reilly, W M Abbott, R C Darling.   

Abstract

One hundred fifty-nine patients with 244 popliteal aneurysms underwent 167 reconstructive procedures. Patients were divided into those with asymptomatic aneurysms, those with acute ischemia secondary to thrombosis or embolism, those with claudication secondary to chronic thrombosis or embolism, and those with local symptoms referable to the aneurysm itself. Patients who underwent successful revascularization were considered to have good early results. Patients with asymptomatic aneurysms had uniformly good results (97.2 percent) as opposed to those presenting with acute (70.7 percent) or chronic symptoms (83.8 percent). Similar statistically significant differences were seen when patients with thrombosis (71.7 percent) or embolism (81.3 percent) were compared with asymptomatic patients. Analysis of late results indicates that if an initial good result was obtained, the late patency rate was independent of type of presentation. Late results were affected by type of conduit employed where life table analysis showed the superiority of saphenous vein over Dacron prosthesis. At 5 year follow-up, 77.2 percent of all saphenous veins were patent whereas only 29.5 percent of Dacron prostheses remained patent.

Entities:  

Mesh:

Year:  1983        PMID: 6837886     DOI: 10.1016/0002-9610(83)90047-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

Review 1.  Management of Asymptomatic Popliteal Artery Aneurysms.

Authors:  Tanner I Kim; Bauer E Sumpio
Journal:  Int J Angiol       Date:  2019-01-02

2.  The management of popliteal aneurysm: the importance of early surgical repair.

Authors:  A W Halliday; P R Taylor; J H Wolfe; A O Mansfield
Journal:  Ann R Coll Surg Engl       Date:  1991-07       Impact factor: 1.891

3.  Problems in diagnosis of popliteal aneurysms.

Authors:  R Downing; R P Grimley; F Ashton; G Slaney
Journal:  J R Soc Med       Date:  1985-06       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.